Edwards Lifesciences Corporation: shareholders and insiders

EWNYSEHealthcare · Orthopedic, Prosthetic & Surgical Appliances & Supplies

Price

$105.43

November 17, 2026Market cap $61.2B

What Ploutos Investor adds for Edwards Lifesciences

Part of Ploutos Investor, €9.99 a month

See the plans
  • The full history: 17 fiscal years, from 2009
  • The estimated fair value, with its range and its certainty
  • The full analysis, 18 a month
  • More questions to the chat on its filings
  • Excel with every year
  • An email when it reports, changes its dividend or an officer buys

Sign in with a free account to see the last 5 fiscal years.

Insiders and their shares

Purchases and sales by officers and directors from Nov 18, 2025 to Nov 13, 2026, from their own Form 4 filings.

25 Form 4s

Bought on the market

–

nobody

Sold on the market

$34M

9 people

From Nov 18, 2025 to Nov 18, 2026, the days the chart shows. Change its range and the figures follow.

How the sales were made, as a share of their value

  • Under a set plan61%
  • The rest39%

By year

Insiders' open-market purchases (up) and sales (down), by value, since Nov 18, 2025, on a log scale: each gridline is ten times the last. From the SEC's quarterly data sets of Form 4 filings.

2026·no buys·sold $29M by 8 people

  • 2025: no buys, sold $5.2M by 7 people
  • 2026: no buys, sold $29M by 8 people
  • Nov 13, 2026Andrew M. DahlSVP, Corporate Controller
    Kind
  • Nov 10, 2026Daniel J. LippisCVP, TAVR
    Kind10b5-1
  • Nov 10, 2026Daniel J. LippisCVP, TAVR
    Kind10b5-1
  • Nov 9, 2026Bernard J ZovighianCEO
    Kind10b5-1
  • Nov 9, 2026Bernard J ZovighianCEO
    Kind10b5-1
  • Nov 9, 2026Bernard J ZovighianCEO
    Kind10b5-1
  • Nov 9, 2026Donald E Bobo JrCVP,Strategy/Corp Development
    Kind10b5-1
  • Nov 9, 2026Donald E Bobo JrCVP,Strategy/Corp Development
    Kind10b5-1
  • Oct 8, 2026Daniel J. LippisCVP, TAVR
    Kind10b5-1
  • Oct 8, 2026Daniel J. LippisCVP, TAVR
    Kind10b5-1
  • Sep 14, 2026Wayne MarkowitzCVP, JAPAC
    Kind
  • Sep 13, 2026Andrew M. DahlSVP, Corporate Controller
    Kind
  • Sep 11, 2026Wayne MarkowitzCVP, JAPAC
    Kind
  • Sep 11, 2026Daveen ChopraCVP, TMTT, Surgical & IHFM
    Kind
  • Sep 11, 2026Daniel J. LippisCVP, TAVR
    Kind10b5-1
  • Sep 11, 2026Daniel J. LippisCVP, TAVR
    Kind10b5-1
  • Aug 31, 2026Andrew M. DahlSVP, Corporate Controller
    Kind
  • Aug 28, 2026Annette BrulsCVP, EMEACLA
    Kind
  • Aug 26, 2026Daveen ChopraCVP, TMTT, Surgical & IHFM
    Kind
  • Aug 26, 2026Daveen ChopraCVP, TMTT, Surgical & IHFM
    Kind
  • Aug 26, 2026Daveen ChopraCVP, TMTT, Surgical & IHFM
    Kind
  • Aug 26, 2026Wayne MarkowitzCVP, JAPAC
    Kind
  • Aug 11, 2026Daniel J. LippisCVP, TAVR
    Kind10b5-1
  • Aug 11, 2026Daniel J. LippisCVP, TAVR
    Kind10b5-1
  • Jul 30, 2026Wayne MarkowitzCVP, JAPAC
    Kind

From the Form 4s insiders file with the SEC within two business days of each trade. Before May 27, 2026 the table lists open-market purchases and sales only (no grants, option exercises or tax withholding), from the SEC's quarterly data sets. The 10b5-1 mark comes from the form's own box (since April 2023) or from a footnote of the filing that names the plan, where there is one.

Insiders and their shares

Every buy and sale by EW's officers and directors from 2006 up to November 17, 2025, 20 more calendar years

Part of Ploutos Investor, €9.99 a month

See the plans

Sign in with a free account to see the last 3 years.

Major holders (over 5%)

Whoever comes to own more than 5% of a class of shares reports it to the SEC on Schedule 13D or 13G. Here is each holder's latest filing.

2 Holders over 5%Apr 29, 2026 Latest filing
  • Vanguard Capital Management
    Share of class7.54%
  • BlackRock, Inc.
    Share of class7.50%
Fell to 5% or less (2)

Holders whose latest filing says they hold 5% or less. After it they need not file again, so what they hold today is not known.

  • The Vanguard Group0.00%Mar 26, 202613G/A
  • Wellington Management Group LLP3.40%Aug 12, 202513G/A

From the Schedule 13D and 13G filed with the SEC since Dec 18, 2024, when they became structured data. A holder who has filed nothing since then is not shown here. A 13D is updated within two business days of any material change, a 13G up to 45 days after the quarter of the change, so the shares are those of the filing. The large managers also appear in the 13Fs.

Well-known managers

Which of the about 30 investment managers we track held the shares at the quarter end, and what they changed from the quarter before.

Sep 30, 2026 quarter end
  • Point72 (Cohen)
    In the quarter-2.9%
  • Viking Global (Halvorsen)
    In the quarter
  • Millennium Mgmt (Englander)
    In the quarter+100%
  • Citadel Advisors (Griffin)
    In the quarter+670%
  • Bridgewater (Dalio)
    In the quarter+60%
  • AQR Capital
    In the quarter-26%
  • Renaissance Technologies
    In the quarter+400%

From the 13Fs managers file with the SEC up to 45 days after each quarter end. They show only long positions on that day, not short sales or what has changed since. No recent 13F: Pershing Square (Ackman), Scion (Burry).

Short interest

How many of the company's shares have been sold borrowed and not yet bought back, twice a month.

On Oct 15, 2026, 1.61% of its shares outstanding were held short, -2.2% since the report before.

Shares held short
9.33M
1.61%
Since the report before9.54M on Sep 30, 2026
-2.2%
2.5
3.80M
More days to cover thanof 4,578 US-listed companies with enough volume
29%
Report date
Oct 15, 2026
  • Oct 31, 2023: Shares held short 11.47M
  • Nov 15, 2023: Shares held short 10.75M
  • Nov 30, 2023: Shares held short 10.05M
  • Dec 15, 2023: Shares held short 13.54M
  • Dec 29, 2023: Shares held short 10.66M
  • Jan 12, 2024: Shares held short 10.87M
  • Jan 31, 2024: Shares held short 9.96M
  • Feb 15, 2024: Shares held short 10.09M
  • Feb 29, 2024: Shares held short 8.44M
  • Mar 15, 2024: Shares held short 10.45M
  • Mar 28, 2024: Shares held short 10.38M
  • Apr 15, 2024: Shares held short 7.38M
  • Apr 30, 2024: Shares held short 9.63M
  • May 15, 2024: Shares held short 8.00M
  • May 31, 2024: Shares held short 8.29M
  • Jun 14, 2024: Shares held short 8.19M
  • Jun 28, 2024: Shares held short 9.14M
  • Jul 15, 2024: Shares held short 7.70M
  • Jul 31, 2024: Shares held short 6.10M
  • Aug 15, 2024: Shares held short 6.34M
  • Aug 30, 2024: Shares held short 6.26M
  • Sep 13, 2024: Shares held short 11.38M
  • Sep 30, 2024: Shares held short 9.61M
  • Oct 15, 2024: Shares held short 8.22M
  • Oct 31, 2024: Shares held short 7.70M
  • Nov 15, 2024: Shares held short 6.87M
  • Nov 29, 2024: Shares held short 8.58M
  • Dec 13, 2024: Shares held short 7.30M
  • Dec 31, 2024: Shares held short 11.31M
  • Jan 15, 2025: Shares held short 9.04M
  • Jan 31, 2025: Shares held short 10.05M
  • Feb 14, 2025: Shares held short 11.90M
  • Feb 28, 2025: Shares held short 8.49M
  • Mar 14, 2025: Shares held short 9.45M
  • Mar 31, 2025: Shares held short 9.54M
  • Apr 15, 2025: Shares held short 7.93M
  • Apr 30, 2025: Shares held short 8.24M
  • May 15, 2025: Shares held short 7.38M
  • May 30, 2025: Shares held short 5.84M
  • Jun 13, 2025: Shares held short 6.07M
  • Jun 30, 2025: Shares held short 7.21M
  • Jul 15, 2025: Shares held short 6.91M
  • Jul 31, 2025: Shares held short 8.00M
  • Aug 15, 2025: Shares held short 8.14M
  • Aug 29, 2025: Shares held short 10.35M
  • Sep 15, 2025: Shares held short 7.26M
  • Sep 30, 2025: Shares held short 7.46M
  • Oct 15, 2025: Shares held short 7.79M
  • Oct 31, 2025: Shares held short 9.12M
  • Nov 14, 2025: Shares held short 9.77M
  • Nov 28, 2025: Shares held short 6.98M
  • Dec 15, 2025: Shares held short 5.64M
  • Dec 31, 2025: Shares held short 7.14M
  • Jan 15, 2026: Shares held short 7.92M
  • Jan 30, 2026: Shares held short 8.09M
  • Feb 13, 2026: Shares held short 7.90M
  • Feb 27, 2026: Shares held short 12.38M
  • Mar 13, 2026: Shares held short 10.95M
  • Mar 31, 2026: Shares held short 9.97M
  • Apr 15, 2026: Shares held short 9.33M
  • Apr 30, 2026: Shares held short 10.54M
  • May 15, 2026: Shares held short 11.39M
  • May 29, 2026: Shares held short 12.16M
  • Jun 15, 2026: Shares held short 11.80M
  • Jun 30, 2026: Shares held short 11.47M
  • Jul 15, 2026: Shares held short 11.35M
  • Jul 31, 2026: Shares held short 10.04M
  • Aug 14, 2026: Shares held short 10.24M
  • Aug 31, 2026: Shares held short 9.02M
  • Sep 15, 2026: Shares held short 9.09M
  • Sep 30, 2026: Shares held short 9.54M
  • Oct 15, 2026: Shares held short 9.33M

As brokers report them to the regulator twice a month, mid-month and at month end, published about eight business days later. A short position is shares sold borrowed and not yet bought back. The share count is the one the company's market value is figured on, from its filings. Days to cover is the shares held short over the average daily volume of the weeks between two reports.

Short sales in daily trading45.1% of the shares in the last 14 sessions' reported trades were short sales.

In the last 14 sessions, 45.1% of the shares in the reported trades were short sales, against 53.0% in the 14 before.

Last 14 sessionsOct 29, 2026 – Nov 17, 2026
45.1%
The 14 beforeOct 9, 2026 – Oct 28, 2026
53.0%
Change
-7.9 pts
Short sales a dayon average, of 2.44M shares
1.10M
More than atof 3,666 US-listed companies, same days
33%
Median of alleight in ten from 34.6% to 63.7%
50.3%
  • Oct 9, 2026: Short sales 63.1%
  • Oct 12, 2026: Short sales 64.9%
  • Oct 13, 2026: Short sales 63.3%
  • Oct 14, 2026: Short sales 64.9%
  • Oct 15, 2026: Short sales 56.3%
  • Oct 16, 2026: Short sales 50.9%
  • Oct 19, 2026: Short sales 52.6%
  • Oct 20, 2026: Short sales 43.2%
  • Oct 21, 2026: Short sales 44.6%
  • Oct 22, 2026: Short sales 43.1%
  • Oct 23, 2026: Short sales 53.6%
  • Oct 26, 2026: Short sales 39%
  • Oct 27, 2026: Short sales 38.2%
  • Oct 28, 2026: Short sales 38.9%
  • Oct 29, 2026: Short sales 36.5%
  • Oct 30, 2026: Short sales 35%
  • Nov 2, 2026: Short sales 50.1%
  • Nov 3, 2026: Short sales 49.3%
  • Nov 4, 2026: Short sales 29.7%
  • Nov 5, 2026: Short sales 44%
  • Nov 6, 2026: Short sales 47%
  • Nov 9, 2026: Short sales 43.9%
  • Nov 10, 2026: Short sales 57.2%
  • Nov 11, 2026: Short sales 41.7%
  • Nov 12, 2026: Short sales 63.1%
  • Nov 13, 2026: Short sales 56.7%
  • Nov 16, 2026: Short sales 53.3%
  • Nov 17, 2026: Short sales 33.1%

This is not the number of shares sold short today: it measures short sales within each day's trading, and only trades made off the exchanges. Much of it is market makers, who sell shares they do not have to fill buyers' orders and cover soon after, so for a heavily traded stock the share is often around half.

What the insiders hold

The shares each insider reports holding after their latest trade (Form 4), for those who traded on the market in the last three years.

1.17M Insiders' shares0.20% Of the company
  • Larry L WoodGlobal President TAVR & Surg
    Directly206.9K
  • Jean-Luc M LemercierCVP, EMEACLA and JAPAC
    Directly186.1K
  • Donald E Bobo JrCVP,Strategy/Corp Development
    Directly53.8K
  • Bernard J ZovighianCEO
    Directly102.6K
  • Theodora MistrasCVP, Chief Financial Officer
    Directly99.9K
  • Kieran GallahueDirector
    Directly–
  • Steven R LorangerDirector
    Directly60.4K
  • Scott B. UllemCVP, Chief Financial Officer
    Directly48.0K
  • Daveen ChopraCVP, TMTT, Surgical & IHFM
    Directly43.9K
  • Daniel J. LippisCVP, TAVR
    Directly40.0K
  • Catherine M. SzymanCVP, Critical Care
    Directly34.8K
  • Heisz Leslie StoneDirector
    Directly30.9K
  • Michael A MussallemDirector
    Directly21.6K
  • Wayne MarkowitzCVP, JAPAC
    Directly19.4K
  • Annette BrulsCVP, EMEACLA
    Directly18.0K
  • Andrew M. DahlSVP, Corporate Controller
    Directly14.6K
  • Robert W.a. SellersSVP, Corporate Controller
    Directly13.1K

A lower bound: it counts only the 17 officers and directors with a market trade since Nov 19, 2023. Anyone who neither bought nor sold since is not here, whatever they hold. The share is against the share count on the latest 10-K's cover.

10b5-1 trading plans

Since 2023 every 10-Q and 10-K says which insiders adopted or ended a trading plan (Rule 10b5-1) in the quarter: when, for how many shares, until when. A plan explains the sales that follow months before they show up on Form 4.

2 Adopted in the last 12 months15 Filings read
  • Bernard J. ZovighianChief Executive Officer and Director
    What happenedAdoptedJul 28, 2026
    Shares145.7K
  • Bernard J. ZovighianChief Executive Officer and Director
    What happenedAdoptedDec 12, 2025
    Shares25.4K
  • Daniel J. LippisCorporate Vice President
    What happenedAdoptedJul 30, 2025
    Shares7,134
  • Scott B. UllemCorporate Vice President, Chief Financial Officer
    What happenedAdoptedJul 29, 2025
    Shares59.7K
  • Bernard J. ZovighianChief Executive Officer and Director
    What happenedAdoptedFeb 28, 2025
    Shares62.8K
  • Donald E. Bobo, Jr.Corporate Vice President, Strategy & Corporate Development
    What happenedAdoptedFeb 27, 2025
    Shares66.7K
  • Larry L. WoodCorporate Vice President and Group President, Transcatheter Aortic Valve Replacement (TAVR) and Surgical Structural Hear
    What happenedAdoptedFeb 27, 2025
    Shares53.7K
  • Bernard J. ZovighianChief Executive Officer and Director
    What happenedAdoptedDec 6, 2024
    Shares14.9K
  • Bernard J. ZovighianChief Executive Officer and Director
    What happenedEndedSep 23, 2024
    Shares25.1K
  • Scott B. UllemCorporate Vice President, Chief Financial Officer
    What happenedAdoptedAug 19, 2024
    Shares56.3K

As the company states them in Item 9B of the 10-K and Part II, Item 5 of the 10-Q, with structured data. A plan allows sales on preset dates and prices. It does not say whether all of them will be executed.

Executive pay

From the Pay versus Performance table every company puts in its proxy statement since 2023: what the chief executive was paid, what was actually paid once the shares vest at year-end values, and how the stock did against the peer group the company itself picked.

2025 Latest year6 Years on record

$17M

Actually paid: $21M

$4.7M

Actually paid: $4.5M

$93

Peers: $127

•Underlying Revenue Growth

From the proxy statement (DEF 14A) of Mar 26, 2026, as filed with the SEC with structured data. Pay in dollars. The company picks its own peer group and measure. DEF 14A

Share repurchases

How many of its own shares the company bought each quarter, at what average price, for how much, and what remains of the program its board authorized, from the table it puts in every 10-Q and 10-K.

$1.2B Repurchases over 4 quarters$1.5B Left in the program
  • Jun 30, 202610-Q
    Amount$159M
  • Mar 31, 202610-Q
    Amount$420M
  • Dec 31, 202510-K
    Amount$40M
  • Sep 30, 202510-Q
    Amount$601M
  • Mar 31, 202510-Q
    Amount$257M
  • Dec 31, 202410-K
    Amount$114M
  • Sep 30, 202410-Q
    Amount$900M
  • Jun 30, 202410-Q
    Amount$150M

From the "Issuer Purchases of Equity Securities" table of the 10-Qs and 10-Ks, read without a model. Only the quarters whose shares times average price agree with the cash the company says it paid for repurchases in its cash-flow statement are shown. The shares include those withheld for officers' taxes. A quarter with an accelerated repurchase shows the table's shares and the cash paid, without an average price. 1 filing(s) not shown, as the table was not read or did not agree with the cash.

The shareholders' vote on pay

The advisory say-on-pay vote at each annual meeting, as the company states it in the 8-K it files after the meeting: how many voted for and against the executives' pay. 90% is the norm. Under 70% proxy advisers expect the board to respond the next year.

89.3% For in 20262 Votes on record
  • 2026May 8, 2026
    For
    89.3%
  • 2022May 4, 2022
    For
    90.0%

From the 8-K (item 5.07) the company files after each annual meeting since 2021, read from the filing's text without a model. A company that votes every three years has empty years. The vote is advisory: the board is not bound by it. 4 filing(s) not read, as the table is not in the usual shape.

The ETFs that hold it

Which of the 345 US equity ETFs we track hold the stock, and at what weight, from the funds' N-PORT filings.

53 ETFs holding it4.75% The largest weight (IHI)
  • IHIiShares U.S. Medical Devices ETF
    Weight in the fund4.75%
  • BLCRiShares Large Cap Core Active ETF
    Weight in the fund2.05%
  • VOTVanguard Mid-Cap Growth Index Fund
    Weight in the fund1.15%
  • XLVState Street(R) Health Care Select Sector SPDR(R) ETF
    Weight in the fund0.91%
  • IYHiShares U.S. Healthcare ETF
    Weight in the fund0.81%
  • VHTVanguard Health Care Index Fund
    Weight in the fund0.72%
  • IXJiShares Global Healthcare ETF
    Weight in the fund0.68%
  • IWSiShares Russell Mid-Cap Value ETF
    Weight in the fund0.51%
  • VOVanguard Mid-Cap Index Fund
    Weight in the fund0.50%
  • IWRiShares Russell Mid-Cap ETF
    Weight in the fund0.37%

53 of the 345 ETFs we track, not of every ETF on the market. The ten largest weights. Positions as each fund filed them in its latest N-PORT.

Institutional investors by quarter

Every manager that reports positions to the SEC (Form 13F), quarter by quarter: how many hold the stock, how many shares and dollars between them, and who entered, left, added or trimmed during the quarter.

1,331 Managers, Q2 2026$47.3B Value of their positions
  • Q3 2025: Managers 1,256
  • Q4 2025: Managers 1,318
  • Q1 2026: Managers 1,296
  • Q2 2026: Managers 1,331

Institutional investors by quarter

The fund managers holding EW, quarter by quarter, from Q1 2013 to Q2 2025, 50 more quarters

Part of Ploutos Investor, €9.99 a month

See the plans

Sign in with a free account to see the last 12 quarters.

Q2 2026: 1,331 managers held 524M shares, worth $47.3B. During the quarter 162 opened a position, 127 closed one, 454 added and 458 trimmed.

The largest holders, Q2 2026

  • BlackRock
    In the quarter+12%
  • Vanguard Capital Management
    In the quarter-0.3%
  • Vanguard Portfolio Management
    In the quarter
  • State Street
    In the quarter
  • JPMorgan Chase
    In the quarter+4.8%
  • Wellington Management Group
    In the quarter-24%
  • Geode Capital Management
    In the quarter+18%
  • Bank of New York Mellon
    In the quarter-16%
  • DZ BANK AG Deutsche Zentral Genossenschafts Bank, Frankfurt am Main
    In the quarter+1.5%
  • Ninety One UK
    In the quarter-0.5%

From the SEC's Form 13F data sets, Q3 2025 to Q2 2026: the long positions of every manager with more than $100 million under management, as filed up to 45 days after each quarter end. Short positions and options are not in them. Shares as reported each quarter, not adjusted for splits. The stock is matched by its CUSIP, through the SEC's fails-to-deliver files.

The full analysis

What do Edwards Lifesciences's filings show?

Who buys and sells is one part of Edwards Lifesciences's picture. The full Ploutos AI analysis reads everything the company has filed and shows what stands behind it, with a source for every figure.

  • A fair value range built from the filings
  • Earnings quality, debt and red flags
  • Insider and institutional moves
  • The case for and the case against

Questions about EW's shareholders

Didn't find what you were looking for?

Ask us
Have EW's insiders bought or sold?

From May 27, 2026 to Nov 13, 2026 Edwards Lifesciences's insiders bought 0 and sold $14M of shares on the market. 55% of the sales were under set 10b5-1 plans.

Which well-known managers hold EW?

7 of the managers we track held the shares on Sep 30, 2026. The largest position was Citadel Advisors (Griffin)'s, worth $362M.

Is every insider transaction a purchase or a sale?

No. Many are part of their pay: share awards, option exercises and shares the company keeps for the tax. Only code P is a purchase with their own money, and code S a sale on the market.

Related pages

The other pages on US stocks, free to read. On the company pages, the last three fiscal years are open to everyone, five with a free account, and every year with Ploutos Investor.

The figures come from the company's SEC filings and the share price, and describe what it has reported. They are not a score or a fair value.